SynthesisThe Cochrane database of systematic reviews2023

Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.

Rolof Gp Gijtenbeek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.